OATL4 displayed more tumorigenic and anti-apoptotic responses to LEN treatment (Viral carcinogenesis [FDA:3.04E-11], Cell cycle FDA:1.48E-4], and Hepatitis B [FDA:2.43E-3]). Here, SLC22A12 is linked to hepatitis B virus infection.